Pyxis Oncology is trading 5.8% down at $2.19 after pricing a dilutive public offering. - The offering includes 36,047,919 shares and warrants for 49,310,352 additional shares; shares and accompanying warrants were priced at $2.90. - It is expected to raise about $110 million upfront, with up to $282.6 million possible if warrants are exercised. - A 19.66% drop followed the September 30 announcement and pricing; closing is expected on or about October 1, subject to customary conditions. Broader markets were mixed.